FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer Announced August 5, 2026
RYBREVANT FASPRO (amivantamab & hyaluronidase-lpuj) receives FDA Priority Review for EGFR- & MET-targeted subQ treatment for advanced head and neck cancer August 5, 2026
Positive Data Demonstrating 100% ORR and 18.2-Month Median OS with Alpha DaRT + Pembrolizumab combo in Locally Advanced or Metastatic Head and Neck Cancer Reported July 28, 2026
FDA Registration-Enabling Ph 3 Confirmatory Study of Multikine® launched in Newly Diagnosed Head and Neck Cancer July 15, 2026
Pyxis Oncology Announces Up to $114M Private Placement Financing to Advance MICVO Through Key Clinical Milestones July 7, 2026
Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Ph 3 Registrational Trial of APG-157 in Head and Neck Cancer July 7, 2026
Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Ph 3 Registrational Trial of APG-157 in Head and Neck Cancer June 30, 2026
NETRIS Pharma Secures €7.25M in Horizon Europe Funding to Advance Ph 2b Clinical Trial in Head and Neck Cancer June 2, 2026
Interim Ph 2 Data for INBRX-106 in 1L HNSCC Demonstrates Potential Costimulatory Benefit Over PD-1 Monotherapy May 12, 2026
Protocol Amendment to NANORAY-312 Ph 3 Head and Neck Cancer Study of for JNJ-1900 (NBTXR3) Announced May 12, 2026
Sidewinder Therapeutics Announces $137 Million Series B Financing to Advance Precision Bispecific ADCs into Clinical Development for Cancer April 15, 2026
Alignment with FDA on Registration Path for CRB-701 in 2L HNSCC and Cervical Cancer Announced April 15, 2026
Transgene and NEC Bio Sign License Agreement to Prepare the Next Steps of the Development of TG4050 in Head and Neck Cancer April 7, 2026
NMPA Accepts New Drug Applications for Toripalimab Subcutaneous Injection Across 12 Indications March 10, 2026
First Interim Analysis in the Global Phase 3 FIERCE-HN Study of ficlatuzumab Completed February 25, 2026
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer February 25, 2026
Adoption of Amended Protocol for Ph 3 VERSATILE-003 Trial Incorporating PFS as Primary Endpoint for Interim Analysis and Potential Accelerated Approval Announced February 25, 2026
FDA Alignment on use of PFS as Primary Endpoint in Ph 3 VERSATILE-003 Trial Announced January 11, 2026
BioAtla and GATC Health Announce a $40M SPV Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ OPSCC January 4, 2026
Six-Year JUPITER-02 Follow-up Results Show LOQTORZI® plus Chemo Nearly Doubles Median OS in NPC December 9, 2025
Immutep and Dr. Reddy’s enters into Strategic Collaboration for Commercialisation of Eftilagimod Alfa December 9, 2025
Merus and Halozyme Enter Global Collaboration and License Agreement to Develop SC Formulation of Petosemtamab November 24, 2025
FDA Meeting Requested to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer November 4, 2025
